Positive topline results from 2 phase 3 studies evaluating faricimab (Vabysmo) in macular edema due to branch and central retinal vein occlusion (BRVO and CRVO) show that faricimab improved vision, according to a press release.
In the BALATON and COMINO studies, patients treated with faricimab injections every 4 weeks for up to 24 weeks, achieved non-inferior visual acuity gains compared to those receiving aflibercept injections every 4 weeks.
“These encouraging data demonstrate that Vabysmo could potentially provide a new treatment option for people living with retinal vein occlusion, a serious retinal vascular condition that can lead to irreversible vision impairment or vision loss,” said Levi Garraway, MD, PhD, chief medical officer and head of Global Product Development, in a press release. “Today’s results add to the extensive evidence supporting Vabysmo’s efficacy in treating multiple types of retinal conditions. We look forward to submitting these data to regulatory authorities.”
Read the full press release here.
Related Content
